 |
市場調査レポート
商品コード
1463320
臨床試験用品の世界市場規模、シェア、成長分析、フェーズ別、用途別 - 産業予測（2024-2031年）Global Clinical Trial Supplies Market Size, Share, Growth Analysis, By Phase(Phase I, Phase II), By Application(Pharmaceutical and Biopharmaceutical, and Contract Research Organizations (CROs)) - Industry Forecast 2024-2031 |
||||||
| 臨床試験用品の世界市場規模、シェア、成長分析、フェーズ別、用途別 - 産業予測（2024-2031年） |
|
出版日: 2024年04月08日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
臨床試験用品の世界市場規模は2022年に29億米ドルと評価され、2023年の30億9,000万米ドルから2031年には51億1,000万米ドルに成長する見通しで、予測期間（2024-2031年）のCAGRは6.5%です。
臨床試験用品の世界市場は、世界化の動向、臨床試験活動の急増、生物製剤やバイオシミラー医薬品の試験の急増に後押しされ、著しい成長を遂げています。バイオ医薬品企業は、研究開発に関連する高コストを軽減すると同時に業務効率を高めるため、サプライチェーンマネジメントシステムを採用しています。特に、臨床試験用品は研究開発費全体のかなりの部分を占めています。さらに、治験中の生物製剤や温度に敏感な医薬品の普及が進んでいることから、臨床試験施設の需要が増加しています。現在、医薬品の約38％が温度感受性を示し、後期医薬品の35％が生物製剤に分類されています。生物製剤に対する需要の高まりは、従来の医薬品に比べて副作用の発生率が低いことに起因しています。市場の成長は、先進国および新興経済諸国におけるバイオシミラーに対する需要の高まりによってさらに促進されます。臨床試験は主に新興経済諸国で行われますが、これはコストが低く、患者募集プロセスが簡素化されているためです。アジア太平洋、ラテンアメリカ、中東欧などの地域は、バイオ医薬品企業にとってかなりの経済的メリットがあります。シンガポールや中国の政府は生物医学研究を促進するために資金を割り当てており、ラテンアメリカは言語の障壁が少ないため患者募集が簡素化されるという利点があります。さらに、新興経済諸国では多様な疾病が存在するため、希少疾病に焦点を当てた臨床試験が促進されます。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次データソースと一次データソース
- 市場規模の推定
- 市場の危機と限界
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
臨床試験用品の世界市場：フェーズ別
- 市場概要
- フェーズI
- フェーズII
- フェーズIII
- フェーズIV
臨床試験用品の世界市場：用途別
- 市場概要
- 医薬品およびバイオ医薬品
- 調査受託機関（CRO）
臨床試験用品の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Catalent, Inc.（US）
- Thermo Fisher Scientific Inc.（US）
- Sharp Packaging Services（US）
- PAREXEL International Corporation（US）
- CordenPharma（Austria）
- Almac Group（UK）
- PCI Pharma Services（US）
- Eurofins Scientific（Luxembourg）
- ICON plc（Ireland）
- Biocair International Ltd（UK）
- DHL（Germany）
- Marken（US）
- Myoderm（US）
- Movianto（Belgium）
- Ancillare LP（US）
- Intertek Group plc（UK）
- KLIFO A/S（Denmark）
- N-SIDE（Belgium）
- Sharp Clinical Services（US）
- PRA Health Sciences, Inc.（US）
The global clinical trial supplies market size was valued at USD 2.9 billion in 2022 and is poised to grow from USD 3.09 billion in 2023 to USD 5.11 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).
The global market for clinical trial supplies has experienced remarkable growth, fueled by the increasing trend of globalization, a surge in clinical trial activities, and the escalating testing of biologics and biosimilar drugs. Biopharmaceutical companies have adopted supply chain management systems to mitigate the high costs associated with research and development while enhancing operational efficiency. Notably, clinical trial supplies constitute a significant portion of the total R&D expenditure. Furthermore, the growing prevalence of biologics and temperature-sensitive drugs under trial has led to an uptick in demand for clinical trial facilities. Presently, approximately 38% of pharmaceutical drugs exhibit temperature sensitivity, with 35% of late-phase pharmaceutical drugs being categorized as biologics. The rising demand for biologics stems from their lower incidence of adverse effects compared to traditional drugs. Market growth is further propelled by the heightened demand for biosimilars across developed and developing economies. Clinical trials predominantly take place in developing economies due to lower costs and simplified patient recruitment processes. Regions such as Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East offer considerable economic advantages to biopharmaceutical companies. Governments in Singapore and China allocate funds to foster biomedical research, while Latin America benefits from simplified patient recruitment owing to reduced language barriers. Moreover, the diverse disease landscape in developing economies facilitates clinical trials focusing on rare diseases.
Top-down and bottom-up approaches were used to estimate and validate the size of the global clinical trial supplies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Clinical Trial Supplies Market Segmental Analysis
The global clinical trial supplies market is segmented based on phase, application, and region. By phase, the market is segmented into phase I, phase II, phase III, and phase IV. By application, the market is segmented into pharmaceutical and biopharmaceutical, and contract research organizations (CROs). By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Clinical Trial Supplies Market
An essential catalyst for the global clinical trial supplies market is the rising need for specialized drug products, particularly biologics. These intricate therapeutic agents demand specific clinical trial supplies to uphold their safety, effectiveness, and stability throughout the trial process. Biologics, distinguished by their complex molecular structure derived from living organisms, serve as vital treatments for a spectrum of ailments. Given their unique characteristics, biologics necessitate specialized clinical trial provisions, including precise refrigeration, tailored packaging materials, and sophisticated temperature monitoring systems. The escalating demand for biologics, fueled by their proven efficacy and reduced adverse effects compared to conventional therapies, is propelling the requirement for specialized clinical trial supplies.
Restraints in the Global Clinical Trial Supplies Market
A significant obstacle facing the global clinical trial supplies market is the exorbitant cost associated with conducting clinical trials. The expenses incurred in conducting these trials have witnessed a substantial increase in recent times, posing a restraint on market expansion. Furthermore, challenges abound in patient recruitment due to the intricacies involved, alongside stringent regulatory requirements that must be adhered to throughout the trial process. These complexities not only impede the growth of the market but also pose barriers for small and mid-sized companies seeking entry, thereby constraining the overall progression of the clinical trial supplies market.
Market Trends of the Global Clinical Trial Supplies Market
An emerging trend in the global clinical trial supplies market is the integration of blockchain technology. This technology presents a decentralized and transparent system capable of tracking and managing the clinical trial supply chain effectively, from production to patient delivery. By enabling real-time tracking of supplies, blockchain technology enhances operational efficiency, minimizes errors, and strengthens data security. As such, its adoption within the clinical trial supplies market is anticipated to rise significantly in the foreseeable future.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Clinical Trial Supplies Market by Phase
- Market Overview
- Phase I
- Phase II
- Phase III
- and Phase IV
Global Clinical Trial Supplies Market by Application
- Market Overview
- Pharmaceutical and Biopharmaceutical
- and Contract Research Organizations (CROs)
Global Clinical Trial Supplies Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Catalent, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sharp Packaging Services (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PAREXEL International Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CordenPharma (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Almac Group (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PCI Pharma Services (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ICON plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocair International Ltd (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DHL (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Marken (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myoderm (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Movianto (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ancillare LP (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intertek Group plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KLIFO A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- N-SIDE (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sharp Clinical Services (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PRA Health Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
